Andrew Bulpin to Assume Leadership of Process Solutions at Merck Millipore
News May 02, 2012
Merck Millipore, the Life Science division of Merck, has announced that Andrew Bulpin, Head of Global Pharmaceutical Chemicals Solutions Sales at Merck Millipore has been appointed Head of the company's Process Solutions Business Unit.
He will assume leadership effective May 14, 2012 and be based at the company's U.S. headquarters in Massachusetts.
Bulpin succeeds Jean-Paul Mangeolle, who is retiring from the company after 28 years of distinguished service.
"Andrew brings a wealth of leadership experience and an in-depth understanding of the life science markets," noted Robert Yates, President of Merck Millipore.
Yates continued, "With a continued focus on helping biopharmaceutical and pharmaceutical manufacturers advance their molecules to market, Andrew has an unprecedented opportunity to evolve the Process Solutions business."
Bulpin joined Millipore Corporation in 2006 as Vice President for the Upstream Processing Business Unit and, in January 2012, assumed leadership of the Services and Solutions Business.
Following the company's acquisition by Merck, he was appointed to his current position.
Prior to Merck Millipore, Bulpin worked at Serologicals Corporation in a number of sales and marketing roles both in the U.S. and Europe.
He holds a Ph.D. in organic chemistry from the Université de Caen, France; an MBA from the University of Strathclyde, Scotland; and a BSc from the University of Sussex, England.
Bulpin also worked as a Post-Doctoral Research Fellow at the Australian National University, Australia.
Absolute Antibody and Kerafast Merge Increasing Access to Unique Reagents and Recombinant Antibody TechnologyNews
Absolute Antibody Ltd., and Kerafast Inc., have announced a merger of the two companies. The merger brings together two companies with a shared commitment to improving the selection of research tools available to the scientific community.READ MORE
Lonza to Establish Cell- and Gene-Therapy Centers of Excellence to Accelerate GrowthNews
Lonza will establish Centers of Excellence for Cell and Gene Therapy to support and accelerate the growth of this priority area for the company.READ MORE